James R. Ravitz
Jamie Ravitz is practice group leader for the firm's FDA Practice (Food & Drug). He also is a member in the life sciences and advertising groups, with a well-rounded practice focused on food and drug law, healthcare, consumer product safety, and advertising. Jamie serves as vice chair of the firm’s consumer product safety committee. Jamie's FDA practice assists clients in navigating regulatory requirements impacting medical device combination products and medical technologies. He also helps clients through all regulatory phases of the approval, manufacture, marketing and retail process.
Blog Posts by James R. Ravitz
On the heels of a January 20, 2017 memorandum freezing the release of any new or pending regulations until they have been reviewed and approved by Trump Administration appointees, the White House issued an executive order on January 30, 2017 requiring agencies and executive departments to “identify at least two existing regulations to be repealed” whenever they propose or promulgate a new regulation.
This article was originally published in Today's Wound Clinic.
Editor’s Note: The following article discusses products characterized as “cellular and/or tissue-based products” (CTPs) by ASTM International. For purposes of this article, the legal and regulatory definition “human cells, tissues, and cellular- and tissue-based products” (HCT/Ps) – is used.
ABOUT ARENT FOX LLP
Arent Fox LLP, founded in 1942, is internationally recognized in core practice areas where business and government intersect. With more than 350 lawyers, the firm provides strategic legal counsel and multidisciplinary solutions to clients that range from Fortune 500 corporations to trade associations. The firm has offices in Los Angeles, New York, San Francisco, and Washington, DC.